Intravesical BCG+interferon-α-2b in prevention of recurrence in transitional cell carcinoma of urinary bladder
Bladder malignancy is the 11th most common cancer in the world with more than 2,00,000 new cases diagnosed every year 90% of these are TCC, of which 75-80% are superficial in nature. Our aim in this study was to find the efficacy, safety and cost effectiveness of a low dose intravesical imnumo-thera...
Main Authors: | Nayan K Mohanty, M N Mandal, A N Sinha, Alok K Jha |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2000-01-01
|
Series: | Indian Journal of Urology |
Subjects: | |
Online Access: | http://www.indianjurol.com/article.asp?issn=0970-1591;year=2000;volume=16;issue=2;spage=129;epage=133;aulast=Mohanty |
Similar Items
-
The comparative study of the effectiveness of BCG and Alfa-Interferon in preventing the recurrence of bladder tumor
by: Ghazimoghadam B (MD), et al.
Published: (1999-05-01) -
Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder
by: N K Mohanty, et al.
Published: (2008-01-01) -
Delayed cystectomy for T 1 G 3 TCC of urinary bladder managed initially by TURBT & intravesical immunotherapy (BCG + interferon) rationale & our result
by: N K Mohanty, et al.
Published: (2004-01-01) -
What have we learned after 30 years of BCG intravesical therapy for superficial bladder cancer?
by: Marcos Tobias-Machado, et al.
Published: (2009-12-01) -
A solitary pulmonary nodule caused by Mycobacterium tuberculosis var. BCG after intravesical BCG treatment: a case report
by: Mariko Itai, et al.
Published: (2021-04-01)